Compounds > cotinine-n-oxide

Page last updated: 2024-11-07

cotinine-n-oxide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cotinine-N-oxide: metabolite of nicotine; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	108114
MeSH ID	M0041858

Synonyms (10)

Synonym
cotinine-n-oxide
FT-0665193
FT-0665192
1-methyl-5-(1-oxidopyridin-1-ium-3-yl)pyrrolidin-2-one
36508-80-2
1-(methyl-d3)-5-(3-pyridinyl)-2-pyrrolidinone n-oxide
(s)-cotinine n-oxide
2-pyrrolidinone,1-methyl-5-(1-oxido-3-pyridinyl)-, (5s)-
AKOS030241280
1-methyl-5-(1-oxidopyridin-5-yl)pyrrolidin-2-one

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (8.33)	18.7374
1990's	5 (41.67)	18.2507
2000's	2 (16.67)	29.6817
2010's	4 (33.33)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.40

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.40 (24.57)
Research Supply Index	2.71 (2.92)
Research Growth Index	5.11 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.40)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	14 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
nicotine 1-n-oxide nicotine 1-N-oxide: RN given refers to unspecified stereoisomer. nicotine N(1')-oxide : A tertiary amine oxide resulting from the oxidation of the pyrrolidine nitrogen of nicotine.	3.09	5	0	pyridines; pyrrolidine N-oxides
nornicotine nornicotine: agricultural or horticultural insecticide; RN given refers to (+-)-isomer; structure	2.98	4	0
norcotinine norcotinine: RN given refers to compound without isomeric designation; metabolite of cotinine	2.72	3	0	pyridines; pyrrolidines
anatabine anatabine: alkaloid found in tobacco; structure	2.48	2	0	bipyridines
2-nitrofluorene 2-nitrofluorene: RN given refers to cpd with locant with nitro moiety in 2 position. 2-nitrofluorene : A nitroarene that is fluorene substituted by a nitro group at position 2.	1.98	1	0	nitroarene	carcinogenic agent; mutagen
n'-nitrosoanabasine N'-nitrosoanabasine: structure; RN given refers to cpd without isomeric designation	1.98	1	0	citraconoyl group
n'-nitrosonornicotine N'-nitrosonornicotine: structure; a potent carcinogen in laboratory animals	2.4	2	0	pyridines; pyrrolidines
4-(n-methyl-n-nitrosamino)-1-(3-pyridyl)-1-butanone 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone: structure; from tobacco smoke	2.4	2	0	nitrosamine; pyridines
nicotine (S)-nicotine : A 3-(1-methylpyrrolidin-2-yl)pyridine in which the chiral centre has S-configuration. The naturally occurring and most active enantiomer of nicotine, isolated from Nicotiana tabacum.	3.79	11	0	3-(1-methylpyrrolidin-2-yl)pyridine	anxiolytic drug; biomarker; immunomodulator; mitogen; neurotoxin; nicotinic acetylcholine receptor agonist; peripheral nervous system drug; phytogenic insecticide; plant metabolite; psychotropic drug; teratogenic agent; xenobiotic
glucuronic acid Glucuronic Acid: A sugar acid formed by the oxidation of the C-6 carbon of GLUCOSE. In addition to being a key intermediate metabolite of the uronic acid pathway, glucuronic acid also plays a role in the detoxification of certain drugs and toxins by conjugating with them to form GLUCURONIDES.. D-glucuronic acid : The D-enantiomer of glucuronic acid.. D-glucopyranuronic acid : A D-glucuronic acid in cyclic pyranose form.	1.98	1	0	D-glucuronic acid	algal metabolite
hydroxycotinine hydroxycotinine: metabolite of nicotine; RN given refers to (S)-isomer; structure. trans-3-hydroxycotinine : An N-alkylpyrrolidine that is cotinine substituted at position C-3 by a hydroxy group (the 3R,5S-diastereomer).	3.71	10	0	N-alkylpyrrolidine; pyridines; pyrrolidin-2-ones; pyrrolidine alkaloid
cotinine n-glucuronide cotinine N-glucuronide: structure given in first source; a major urinary metabolite of nicotine	2.39	2	0
anabasine Anabasine: A piperidine botanical insecticide.. (S)-anabasine : The (S)-enantiomer of anabasine.. anabasine : A pyridine alkaloid that is pyridine substituted by a piperidin-2-yl group at position 3.	2.48	2	0	anabasine
n'-nitrosoanatabine N'-nitrosoanatabine: nitroso cpd prepared from alkaloid anatabine; structure given in first source	1.98	1	0
cotinine Cotinine: The N-glucuronide conjugate of cotinine is a major urinary metabolite of NICOTINE. It thus serves as a biomarker of exposure to tobacco SMOKING. It has CNS stimulating properties.. (-)-cotinine : An N-alkylpyrrolidine that consists of N-methylpyrrolidinone bearing a pyridin-3-yl substituent at position C-5 (the 5S-enantiomer). It is an alkaloid commonly found in Nicotiana tabacum.	4.79	12	0	N-alkylpyrrolidine; pyridines; pyrrolidin-2-ones; pyrrolidine alkaloid	antidepressant; biomarker; human xenobiotic metabolite; plant metabolite
nicotine n-glucuronide nicotine N-glucuronide: a metabolite of nicotine. (S)-nicotinium N-alpha-D-glucosiduronate : An N-glycosylpyridine that is the N-alpha-D-glucosiduronyl derivative of (S)-nicotine.	2.39	2	0	iminium betaine; N-glycosylpyridine	metabolite

Condition	Indicated	Relationship Strength	Studies	Trials
Diabetes Mellitus, Adult-Onset [description not available]	0	3.06	1	0
Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.	0	3.06	1	0
Smoking Cessation Discontinuing the habit of SMOKING.	0	3.06	1	0
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	0	2.08	1	0
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	0	2.04	1	0
Mouth Diseases Diseases involving the MOUTH.	0	2.68	3	0
Leukoedema, Oral A disorder of the buccal mucosa resembling early leukoplakia, characterized by the presence of filmy opalescence of the mucosa in the early stages to a whitish gray cast with a coarsely wrinkled surface in the later stages, associated with intracellular edema of the spinous or malpighian layer. (Dorland, 27th ed)	0	2.39	2	0
Keratosis, Oral [description not available]	0	1.99	1	0
Tongue, Hairy A benign condition of the tongue characterized by hypertrophy of the filiform papillae that give the dorsum of the tongue a furry appearance. The color of the elongated papillae varies from yellowish white to brown or black, depending upon staining by substances such as tobacco, food, or drugs. (Dorland, 27th ed)	0	1.99	1	0
Leukoplakia, Oral A white patch seen on the oral mucosa. It is considered a premalignant condition and is often tobacco-induced. When evidence of Epstein-Barr virus is present, the condition is called hairy leukoplakia (LEUKOPLAKIA, HAIRY).	0	1.99	1	0